|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Capitalization1 |
327 | 286 | 559 | 605 | 827 | 415 | - | - |
| Enterprise Value (EV)1 |
327 | 286 | 559 | 605 | 827 | 415 | 415 | 415 |
| P/E ratio |
-2,65x | -1,65x | -5,09x | -3,03x | -29,3x | -1,71x | -2,01x | -2,09x |
| Yield |
- | - | - | - | - | - | - | - |
| Capitalization / Revenue |
7,62x | 7,76x | 3,73x | 6,86x | 2,80x | 6,67x | 4,33x | 3,33x |
| EV / Revenue |
7,62x | 7,76x | 3,73x | 6,86x | 2,80x | 6,67x | 4,33x | 3,33x |
| EV / EBITDA |
- | - | - | - | - | - | - | - |
| Price to Book |
- | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) |
100 183 | 119 983 | 137 361 | 190 149 | 256 831 | 270 991 | - | - |
| Reference price (USD) |
3,26 | 2,38 | 4,07 | 3,18 | 3,22 | 1,53 | 1,53 | 1,53 |
| Announcement Date |
03/15/2018 | 03/14/2019 | 03/12/2020 | 03/15/2021 | 03/01/2022 | - | - | - |
1 USD in Million |
|
|
| Income Statement Evolution (Annual data) |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net sales1 |
42,9 | 36,8 | 150 | 88,2 | 296 | 62,2 | 95,8 | 124 |
| EBITDA |
- | - | - | - | - | - | - | - |
| Operating profit (EBIT)1 |
-104 | -124 | -70,1 | -115 | 25,7 | -176 | -167 | -164 |
| Operating Margin |
-242% | -337% | -46,7% | -130% | 8,71% | -284% | -174% | -132% |
| Pre-Tax Profit (EBT)1 |
-121 | -162 | -112 | -183 | -28,7 | -253 | -242 | -241 |
| Net income1 |
-121 | -160 | -112 | -183 | -24,1 | -238 | -235 | -238 |
| Net margin |
-282% | -435% | -74,3% | -207% | -8,16% | -383% | -245% | -191% |
| EPS2 |
-1,23 | -1,44 | -0,80 | -1,05 | -0,11 | -0,89 | -0,76 | -0,73 |
| Dividend per Share |
- | - | - | - | - | - | - | - |
| Announcement Date |
03/15/2018 | 03/14/2019 | 03/12/2020 | 03/15/2021 | 03/01/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
| Income Statement Evolution (Quarterly data) |
|
|
Fiscal Period: December
|
2019 Q4 |
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
| Net sales1 |
34,5 | 15,1 | 26,9 | 14,8 | 31,3 | 11,7 | 10,7 | 253 | 20,3 | 25,9 | 18,7 | 12,0 | 15,0 |
| EBITDA |
- | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating profit (EBIT)1 |
-19,3 | -33,5 | -33,3 | -32,6 | -20,9 | -43,5 | -66,4 | 188 | -54,0 | -35,5 | -43,7 | -47,9 | -44,1 |
| Operating Margin |
-55,9% | -222% | -123% | -220% | -66,9% | -371% | -619% | 74,1% | -267% | -137% | -234% | -398% | -295% |
| Pre-Tax Profit (EBT)1 |
-30,9 | -45,3 | -48,2 | -51,6 | -37,7 | -54,4 | -84,0 | 177 | -67,6 | -50,6 | -61,1 | -69,2 | -64,5 |
| Net income1 |
-30,9 | -45,3 | -48,2 | -51,6 | -37,7 | -54,4 | -84,0 | 177 | -65,6 | -48,4 | -59,1 | -64,2 | -59,7 |
| Net margin |
-89,4% | -299% | -179% | -348% | -121% | -464% | -783% | 70,1% | -324% | -186% | -316% | -534% | -399% |
| EPS2 |
-0,22 | -0,31 | -0,28 | -0,28 | -0,20 | -0,27 | -0,37 | 0,72 | -0,29 | -0,19 | -0,23 | -0,25 | -0,22 |
| Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date |
03/12/2020 | 05/07/2020 | 08/06/2020 | 10/29/2020 | 03/15/2021 | 05/06/2021 | 08/09/2021 | 11/09/2021 | 03/01/2022 | 05/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net Debt |
- | - | - | - | - | - | - | - |
| Net Cash position |
- | - | - | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
- | - | - | - | - | - | - | - |
| Free Cash Flow |
-97,3 | -135 | -23,3 | -143 | -23,7 | - | -312 | -329 |
| ROE (Net Profit / Equities) |
- | - | - | - | - | - | - | - |
| Shareholders' equity1 |
- | - | - | - | - | - | - | - |
| ROA (Net Profit / Asset) |
- | - | - | - | - | - | - | - |
| Assets1 |
- | - | - | - | - | - | - | - |
| Book Value Per Share |
- | - | - | - | - | - | - | - |
| Cash Flow per Share |
- | - | - | - | - | - | - | - |
| Capex1 |
3,12 | 3,60 | 4,66 | 3,47 | 33,8 | 2,65 | 5,20 | 6,00 |
| Capex / Sales |
7,28% | 9,78% | 3,10% | 3,93% | 11,4% | 4,26% | 5,43% | 4,82% |
| Announcement Date |
03/15/2018 | 03/14/2019 | 03/12/2020 | 03/15/2021 | 03/01/2022 | - | - | - |
1 USD in Million |
|
|
|
|
|
Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate |
| Capitalization (USD) |
414 616 210 |
| Net sales (USD) |
295 665 000 |
| Number of employees |
441 |
| Sales / Employee (USD) |
670 442 |
| Free-Float |
89,9% |
| Free-Float capitalization (USD) |
372 752 168 |
| Avg. Exchange 20 sessions (USD) |
7 674 261 |
| Average Daily Capital Traded |
1,85% |
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
Previous period
